Imagen de Portada

Could Disease Duration Influence Response to Dupilumab in Patients With Atopic Dermatitis? A Retrospective Real‐Life Study

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Edoardo Mortato, Marina Talamonti, Claudia Paganini, Alfredo Belcastro, Lorenzo Tofani, Luca Bianchi, Marco Galluzzo
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	International Journal of Dermatology
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Predictive Factors of Super‐Responder Status to Dupilumab in Adult Atopic Dermatitis: A Real‐World Monocentric Study
por: Edoardo Mortato, et al.
Publicado: (2026)

Ocular complications in patients with psoriasis: Is dry eye associated with psoriasis?
por: Marina Talamonti, et al.
Publicado: (2024)

Real‐World Experience of Dupilumab in Children and Adolescents With Atopic Dermatitis in Argentina
por: Margarita Larralde, et al.
Publicado: (2025)

A Pediatric Case of Severe Atopic Dermatitis on Dupilumab Treatment and Pulmonary Tuberculosis
por: Maria Efenesia Baffa, et al.
Publicado: (2025)

Concordance Between Patient‐ and Physician‐Reported Improvement With Dupilumab in Atopic Dermatitis
por: Geena Conde, et al.
Publicado: (2026)

Long‐Term Safety and Efficacy of Dupilumab in Pediatric Atopic Dermatitis Patients
por: Hilla Bauch-Eigner, et al.
Publicado: (2025)

Real‐World Efficacy and Safety of Dupilumab for Atopic Dermatitis in the Israeli Population
por: Raz Tshuva, et al.
Publicado: (2025)

A Real‐World Retrospective Cohort Study on the Use of Dupilumab for Severe Atopic Dermatitis in Patients Aged 6 Months to 16 Years
por: Laura Wheller, et al.
Publicado: (2025)

Combination Therapy With Upadacitinib and Dupilumab for Severe Atopic Dermatitis
por: Amaia Barrutia‐Etxebarria, et al.
Publicado: (2025)

The Use of Dupilumab for Severe Atopic Dermatitis in Patients Aged Under 12‐Years
por: Laura Wheller, et al.
Publicado: (2026)

Evaluating Outcomes of Live‐Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis
por: Grace Eleanor Sessler Bruess, et al.
Publicado: (2025)

An Observational Study of Early Treatment Response and Predictors of Dupilumab in the Treatment of Moderate‐to‐Severe Atopic Dermatitis
por: Sisi Deng, et al.
Publicado: (2024)

Dupilumab in Combination With JAK Inhibitor for Refractory Moderate‐to‐Severe Atopic Dermatitis
por: Xiaoting Song, et al.
Publicado: (2024)

Successful Use of Dupilumab in the Treatment of Acquired Perforating Dermatosis Associated with Atopic Dermatitis
por: Niccolò Gori, et al.
Publicado: (2024)

Real‐World Experience of 3‐Year Treatment With Dupilumab: Significant Decrease in Circulating Neutrophils and Eosinophils in Japanese Patients With Atopic Dermatitis
por: Hideyuki Nakajima, et al.
Publicado: (2024)

Clinical Outcomes of Tralokinumab and Lebrikizumab in Japanese Atopic Dermatitis Patients With Persistent Head and Neck Dermatitis After Long‐Term Treatment With Dupilumab: A Single‐Center Retrospective Study
por: Ayu Watanabe, et al.
Publicado: (2025)

Dupilumab‐Associated Ocular Surface Disease in Pediatric Atopic Dermatitis: A Single‐Center Asian Experience
por: Amanda Xin Yi Yap, et al.
Publicado: (2024)

Dupilumab‐Induced Psoriasis in an Adolescent With Severe Atopic Dermatitis: Successful Management With Abrocitinib
por: Grigorios Theodosiou, et al.
Publicado: (2026)

Real‐Life Effectiveness of Abrocitinib and Predictors of Response in Adults With Moderate‐To‐Severe Atopic Dermatitis
por: Eugenia Veronica Di Brizzi, et al.
Publicado: (2026)

Dupilumab's Real‐World Efficacy and Safety Across Age Groups for Children and Adolescents With Paediatric Atopic Dermatitis
por: Paul Sun Woo Kim, et al.
Publicado: (2026)

Dupilumab Treatment for Atopic Dermatitis Is Associated With Decreased Risk of Otitis Media and Related Surgical Procedures: A Retrospective Cohort Study
por: Matthew H. Lanehart, et al.
Publicado: (2025)

The Usefulness of Atopic Dermatitis Control Tool in Upadacitinib Treatment for Patients with Atopic Dermatitis
por: Teppei Hagino, et al.
Publicado: (2024)

Phenotypic Switch From Atopic Dermatitis to Psoriasis During Dupilumab Therapy: A Real‐Life Experience From a Tertiary Referral Center
por: Alessandra Chiei Gallo, et al.
Publicado: (2025)

Increased Risk of Cutaneous T‐Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis
por: Jenna Mandel, et al.
Publicado: (2024)

Refractory Facial Cutaneous B‐Cell Pseudolymphoma in an Atopic Patient Responsive to Dupilumab
por: Salih Mishlab, et al.
Publicado: (2025)

Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families
por: Maria Gnarra Buethe, et al.
Publicado: (2026)

Dual Dupilumab and Omalizumab Therapy in Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma: Real‐World Experience From an Eight‐Patient Case Series
por: Jessica McClatchy, et al.
Publicado: (2025)

Serum YKL‐40 Levels as a Biomarker for Disease Severity and Therapeutic Response in Atopic Dermatitis Patients
por: Jiaming Fan, et al.
Publicado: (2025)

Effect of Dupilumab Therapy on Patch Test Results for Atopic Contact Dermatitis: A Systematic Review
por: Dennis Chu, et al.
Publicado: (2025)

Moisturizer Use in Children With Atopic Dermatitis: Real‐Life Practice, Beliefs, and Challenges Among a Cohort of Jordanian Patients
por: Jihan Muhaidat, et al.
Publicado: (2024)

Retrospective Assessment of Social Rejection Related to Atopic Dermatitis During Childhood and Adolescence: The Scars of Life—Eczema Study
por: Bruno Halioua, et al.
Publicado: (2026)

Atopic Dermatitis
Publicado: (2026)

Diagnostic Implications of Dupilumab‐Refractory Atopic Dermatitis: Risk of Underlying Cutaneous T‐Cell Lymphoma and the Role of Skin Biopsy
por: Sahithi Talasila, et al.
Publicado: (2026)

Patient‐Reported Impact of Atopic Dermatitis on Pediatric and Adolescent Patients With Moderate‐To‐Severe Disease: Results of a Real‐World, Cross‐Sectional Survey
por: Lawrence F. Eichenfield, et al.
Publicado: (2025)

Real‐World Experience With Dupilumab Treatment in Children and Adolescents With Moderate‐to‐Severe Atopic Dermatitis in a Clinically Diverse Population: A 52‐Week Multicenter Study
por: María Fernanda Ordóñez-Rubiano, et al.
Publicado: (2026)

Differential Cutaneous Responses to Baricitinib in Concomitant Lichen Planus and Localized Eczematous Dermatitis in an Atopic Patient
por: Shiomi Iwata, et al.
Publicado: (2026)

A Perspective on Potential Disease Modification in Atopic Dermatitis
por: Francisco Javier Melgosa Ramos, et al.
Publicado: (2025)

The Role of Macrophages in Atopic Dermatitis
por: Xue Chen, et al.
Publicado: (2026)

Long‐Term Effectiveness of Dupilumab in Moderate‐to‐Severe Atopic Dermatitis Across Different Body Regions in Extended Dosing‐Interval Regimens: A Real‐World Chinese Study
por: Yunmin Zou, et al.
Publicado: (2025)

Efficacy and Safety of Dupilumab in Children Aged 6 months–11 years Old With Atopic Dermatitis: A Systematic Review and Meta‐Analysis
por: Hua Wei, et al.
Publicado: (2026)